March 19, 2020 / 9:24 PM / 22 days ago

BRIEF-Lexicon Pharmaceuticals Provides An Update On The Sotagliflozin Type 2 Diabetes Program

March 19 (Reuters) - Lexicon Pharmaceuticals Inc:

* LEXICON PHARMACEUTICALS PROVIDES AN UPDATE ON THE SOTAGLIFLOZIN TYPE 2 DIABETES PROGRAM

* LEXICON PHARMACEUTICALS - TO CLOSE OUT EARLY TWO LONG-TERM OUTCOMES STUDIES OF SOTAGLIFLOZIN, SCORED & SOLOIST

* LEXICON - DECISION TO CLOSE OUT STUDIES EARLY BASED ON ASSESSMENT THAT NEAR-TERM PARTNERSHIP SUFFICIENT TO FUND STUDIES TO COMPLETION IS NOW UNLIKELY

* LEXICON - DECISION TO CLOSE OUT STUDIES EARLY ALSO BASED ON UNCERTAINTIES RELATING TO EFFECTS OF COVID-19 PANDEMIC

* LEXICON PHARMACEUTICALS - WILL PROVIDE FURTHER INFORMATION REGARDING CLOSE-OUT OF STUDIES ON Q1 RESULTS CONFERENCE CALL IN EARLY MAY Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below